Benjamin Zeskind

873 total citations · 1 hit paper
17 papers, 507 citations indexed

About

Benjamin Zeskind is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Benjamin Zeskind has authored 17 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Immunology and 5 papers in Cancer Research. Recurrent topics in Benjamin Zeskind's work include Computational Drug Discovery Methods (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Immunotherapy and Immune Responses (3 papers). Benjamin Zeskind is often cited by papers focused on Computational Drug Discovery Methods (3 papers), Colorectal Cancer Treatments and Studies (3 papers) and Immunotherapy and Immune Responses (3 papers). Benjamin Zeskind collaborates with scholars based in Israel, United States and Mexico. Benjamin Zeskind's co-authors include Rebecca Kusko, Jeffrey Ross, Ian J. Reynolds, I. Grossman, Spyros Papapetropoulos, Gregory Koytiger, Deepak Kumar, Yoonjeong Cha, Winston Timp and Daniel J. Ehrlich and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Nature Methods.

In The Last Decade

Benjamin Zeskind

17 papers receiving 494 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug repurposing from the perspective of pharmaceutical companies

2017 269 citations Yoonjeong Cha, Ian J. Reynolds et al. British Journal of Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin Zeskind Israel	7	202	105	58	57	55	17	507
Joshua F. Apgar United States	11	257 1.3×	71 0.7×	48 0.8×	44 0.8×	43 0.8×	31	598
John G. Houston United States	11	231 1.1×	75 0.7×	29 0.5×	68 1.2×	14 0.3×	15	463
Konstantin I. Popov United States	13	304 1.5×	84 0.8×	43 0.7×	42 0.7×	66 1.2×	31	553
Daniel Muthas Sweden	16	305 1.5×	178 1.7×	181 3.1×	31 0.5×	17 0.3×	33	863
Pierre Sabatier Sweden	13	415 2.1×	55 0.5×	60 1.0×	33 0.6×	17 0.3×	36	649
Jamie Munro United Kingdom	3	160 0.8×	113 1.1×	29 0.5×	67 1.2×	16 0.3×	4	411
Mohan Rao United States	7	215 1.1×	153 1.5×	47 0.8×	29 0.5×	15 0.3×	13	446
Sarah Kolitz United States	15	506 2.5×	30 0.3×	53 0.9×	99 1.7×	11 0.2×	25	744
Jyotika Varshney United States	15	207 1.0×	67 0.6×	39 0.7×	28 0.5×	6 0.1×	25	493
Katarzyna Śmietana United States	8	267 1.3×	59 0.6×	52 0.9×	41 0.7×	10 0.2×	12	543

Countries citing papers authored by Benjamin Zeskind

Since Specialization

Citations

This map shows the geographic impact of Benjamin Zeskind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Zeskind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Zeskind more than expected).

Fields of papers citing papers by Benjamin Zeskind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Zeskind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Zeskind. The network helps show where Benjamin Zeskind may publish in the future.

Co-authorship network of co-authors of Benjamin Zeskind

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Zeskind. A scholar is included among the top collaborators of Benjamin Zeskind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Zeskind. Benjamin Zeskind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Spira, Alexander I., Anne C. Pavlick, Bo Ma, et al.. (2024). 1524P Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors. Annals of Oncology. 35. S930–S931. 2 indexed citations

Hall, Brett M., Anna Travesa, Amy Axel, et al.. (2022). 449 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors. Regular and Young Investigator Award Abstracts. A469–A469. 2 indexed citations

Kim, Jason, et al.. (2021). A primer on applying AI synergistically with domain expertise to oncology. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1876(1). 188548–188548. 6 indexed citations

King, Peter, Amy Axel, Kevin Fowler, et al.. (2021). Abstract P240: Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model. Molecular Cancer Therapeutics. 20(12_Supplement). P240–P240. 1 indexed citations

Kolitz, Sarah, et al.. (2020). 664 Applying advanced data analysis to immunotherapy drug discovery for Uveal Melanoma. Regular and Young Investigator Award Abstracts. A398.2–A399. 1 indexed citations

Kolitz, Sarah, Jason Z. Kim, Jenny Zhang, et al.. (2020). 477 Deep learning to drive COVID-19 rapid drug repurposing. SHILAP Revista de lepidopterología. A293.1–A293. 2 indexed citations

Loupe, Pippa S., Vera Weinstein, Sarah Kolitz, et al.. (2018). Response to the Letter-to-the Editor by Cohen et al. concerning our eNeurologicalSci article, Melamed-Gal, et al. Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone. eNeurologicalSci 2018;12:19–30.https://doi.org/10.1016/j.ensci.2018.05.006. eNeurologicalSci. 13. 53–55. 1 indexed citations

Ung, Matthew, Kevin Fowler, Jason Funt, et al.. (2018). Abstract 1509: Cachexia: Leveraging transcriptomics to identify potential therapeutics. Cancer Research. 78(13_Supplement). 1509–1509. 1 indexed citations

Ung, Matthew, Jason Funt, Andrew C. Lysaght, et al.. (2018). Abstract 5177: Metastasis: Leveraging transcriptomics to identify potential therapeutics. Cancer Research. 78(13_Supplement). 5177–5177. 1 indexed citations

10.

Cha, Yoonjeong, Ian J. Reynolds, Deepak Kumar, et al.. (2017). Drug repurposing from the perspective of pharmaceutical companies. British Journal of Pharmacology. 175(2). 168–180. 269 indexed citations breakdown →

11.

Grossman, Iris, Sarah Kolitz, Benjamin Zeskind, et al.. (2017). Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model. Annals of the New York Academy of Sciences. 1407(1). 75–89. 6 indexed citations

12.

Kolitz, Sarah, Fadi Towfic, Daphna Laifenfeld, et al.. (2015). Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Journal of Neuroimmunology. 290. 84–95. 17 indexed citations

13.

Kolitz, Sarah, Fadi Towfic, Jason Funt, et al.. (2015). Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Scientific Reports. 5(1). 10191–10191. 15 indexed citations

14.

Fowler, Kevin, Jason Funt, Maxim N. Artyomov, et al.. (2015). Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets. Scientific Reports. 5(1). 14324–14324. 14 indexed citations

15.

Grossman, I., et al.. (2015). Rates of Adverse Events and Multiple Sclerosis Relapses Before and After Introduction of a Purported Generic Glatiramer Acetate in mexico: Results from a Large Patient Support Program in Mexico. Value in Health. 18(7). A877–A877. 1 indexed citations

16.

Towfic, Fadi, Jason Funt, Kevin Fowler, et al.. (2014). Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic. PLoS ONE. 9(1). e83757–e83757. 31 indexed citations

17.

Zeskind, Benjamin, et al.. (2007). Nucleic acid and protein mass mapping by live-cell deep-ultraviolet microscopy. Nature Methods. 4(7). 567–569. 137 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact